Repligen (RGEN) Hits New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Repligen ( RGEN) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Repligen as such a stock due to the following factors:

  • RGEN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $14.0 million.
  • RGEN has traded 68,971 shares today.
  • RGEN is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in RGEN with the Ticky from Trade-Ideas. See the FREE profile for RGEN NOW at Trade-Ideas

More details on RGEN:

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. RGEN has a PE ratio of 124.4. Currently there are 2 analysts that rate Repligen a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Repligen has been 400,800 shares per day over the past 30 days. Repligen has a market cap of $1.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.89 and a short float of 12.7% with 8.77 days to cover. Shares are up 57.1% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Drug Stocks Find Trump Animus a Bitter Pill

5 Health Care Stocks Set to Bounce

Repligen Has More Upside Ahead

Repligen Has More Upside Ahead

Trade-Ideas: Repligen (RGEN) Is Today's Weak On High Relative Volume Stock

Today's Dead Cat Bounce Stock Is Repligen (RGEN)